Identification of an intrinsic lysophosphatidic acid acyltransferase activity in the lipolytic inhibitor G0/G1 switch gene 2 (G0S2)
The researchers also noted that 23.5% (95% CI, 22.3-24.8) of people meeting FDA indications for tirzepatide reported using medications that may slow gastrointestinal motility, which could increase gastrointestinal adverse effects when combined with any GLP-1 receptor agonist
Nutrition Considerations for the Stack Nutrition strategy during a Tirzepatide and HGH protocol requires adjustments from typical dieting approaches
Frequently Asked Questions About Medical Weight Loss Injections How quickly will I see results with weight loss injections
A report from the EMAs PRAC, published on 12 April 2024, said: After reviewing the available evidence from non-clinical studies, clinical trials, post-marketing surveillance data and the available studies the PRAC considers that no update to the product information is warranted. The PRAC statement said that market authorisation holders would continue to monitor events, including new studies, as part of their pharmacovigilance activities